- EASO released a new evidence-based algorithm for obesity treatment.
- Semaglutide and tirzepatide achieved the greatest weight reduction.
- Tirzepatide improved sleep apnea and liver disease; semaglutide reduced cardiovascular events.
- Barbara McGowan, MD, emphasized tailoring therapy to comorbidities and patient goals.
- The framework supports clinical judgment and highlights evidence gaps in extreme BMI ranges.
Source: Nature Medicine
